The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy | Oncology
Obinutuzumab in hematologic malignancies: Lessons learned to date - ScienceDirect
Structure of obinutuzumab and the Fc-attached glycan tree modified by... | Download Scientific Diagram
Obinutuzumab for the treatment of non-Hodgkin lymphomas
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma - Clinical Lymphoma, Myeloma and Leukemia
Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. - Abstract - Europe PMC
Obinutuzumab for the treatment of non-Hodgkin lymphomas
Rituximab - Wikipedia
Final Stage 1 Results of the Phase III CLL11 Trial of Chlorambucil with Obinutuzumab or Rituximab in Previously Untreated CLL | Research To Practice
![PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/33f339e9d609e1fa7d39a952cafd3e938b2119d3/3-Table2-1.png "PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar")
PDF] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab | Semantic Scholar
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. - Abstract - Europe PMC
Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions | Research To Practice
Genentech: Gazyva® (obinutuzumab)
Obinutuzumab in chronic lymphocytic leukemia: design, development and | DDDT
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways - ScienceDirect
GAZYVA® (obinutuzumab) Proposed Mechanism of Action | CLL
A tale of two antibodies: obinutuzumab versus rituximab - Freeman - 2018 - British Journal of Haematology - Wiley Online Library
Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and. - ppt download
Mechanism of action of obinutuzumab. Notes: (A) Modification of the... | Download Scientific Diagram
The proposed mechanisms of action for rituximab, a chimeric monoclonal... | Download Scientific Diagram
The clinical development of obinutuzumab for the treatment of follicul | CMAR
Rituximab mechanisms of action; the three major independent mechanisms... | Download Scientific Diagram
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies | SpringerLink
